Alchahin, Adele M.
Mei, Shenglin http://orcid.org/0000-0001-8258-5898
Tsea, Ioanna
Hirz, Taghreed
Kfoury, Youmna
Dahl, Douglas
Wu, Chin-Lee
Subtelny, Alexander O.
Wu, Shulin
Scadden, David T.
Shin, John H.
Saylor, Philip J. http://orcid.org/0000-0003-4849-3695
Sykes, David B. http://orcid.org/0000-0002-9788-0221
Kharchenko, Peter V.
Baryawno, Ninib http://orcid.org/0000-0001-6054-4163
Funding for this research was provided by:
Barncancerfonden
Cancerfonden
Vetenskapsrådet
Article History
Received: 11 November 2021
Accepted: 13 September 2022
First Online: 30 September 2022
Competing interests
: P.V.K. serves on the Scientific Advisory Board to Celsius Therapeutics Inc. and Biomage Inc. D.T.S. is a director and shareholder for Agios Therapeutics and Editas Medicines; a founder, director, shareholder, and scientific advisory board member for Magenta Therapeutics and LifeVault Bio, a shareholder and founder of Fate Therapeutics, and a director, founder, and shareholder for Clear Creek Bio, a consultant for FOG Pharma and VCanBio, and a recipient of sponsored research funding from Novartis. D.B.S. is a founder, consultant, and shareholder for Clear Creek Bio. The remaining authors declare no competing interests.